New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by ...

Patients who have undergone coronary artery bypass graft (CABG) surgery for acute coronary syndrome (ACS) derive particular benefit from the addition of ezetimibe to statin therapy. This finding comes ...

Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...

The NPPA has capped retail prices for 42 new drugs, covering diabetes, hypertension, and women's health, to keep chronic ...

New research suggests that pairing a moderate-intensity statin with ezetimibe can match the cardiovascular benefits of high-intensity statins while reducing the likelihood of developing type 2 ...

The National Pharmaceutical Pricing Authority (NPPA) has revised the retail prices of 42 drug formulations under the Drugs ...

Unfavorable lipid profiles are becoming a larger concern in primary care. A noted increase in dyslipidemia among children and ...